Guardant Health Inc

Guardant Health Inc is engaged in the treatment of cancer through precision oncology. The company develops blood-based tests and provides data sets and analytics for use in the US and over 60 other countries. It also offers development and support services to medical institutions and biopharmaceutical companies to aid translational science research. Incorporated in 2011, Guardant Health has its headquarters in Redwood City, California. The products offered by Guardant Health include Guardant 360 CDx, a liquid biopsy test for tumour mutations that covers the 55 cancer genes most essential to medical care; Guardant360 TissueNext, a tissue sample test that can be run as a follow-up to Guardant 360 CDx if necessary; Guardant360 Response, a blood-based test for early indications of molecular or tumour DNA response to treatment; Guardant Reveal, a blood-based test for early detection of residual or recurring cancer especially in patients with Stage II or III colorectal cancer; and GuardantOMNI, a liquid biopsy test covering 500 cancer-related genes for analysis of circulating tumour DNA in the blood. For biopharmaceutical research, the company provides sample analysis services and data through GuardantEXPLORE, GuardantCOMPANION, GuardantConnect, and the GuardantINFORM platform. As of 2021, the company is developing LUNAR-2, a test for early detection of circulating tumour DNA in the blood. Guardant Health is listed on the NASDAQ and uses the ticker GH. Monitor the GH share price by adding it to your eToro watchlist.